NCT00480025

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,278 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Conditions

• Lung Cancer, Non-Small Cell

Interventions

Type	Name	Description
BIOLOGICAL	GSK1572932A Antigen-Specific Cancer Immunotherapeutic	Intramuscular administration, 13 doses
BIOLOGICAL	Placebo Control	Intramuscular administration, 13 doses

Timeline

• Start date: 2007-10-04
• Primary completion: 2013-12-06
• Completion: 2014-09-23
• First posted: 2007-05-30
• Last updated: 2020-12-22
• Results posted: 2019-01-30

Locations

620 sites across 34 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Netherlands, Norway, Poland, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Ukraine, United Kingdom